Dr. Jeffrey P. Letzer, DO
Hematology & Oncology (Hematology & Oncology Physician)
11050 Parkview Circle Dr
Fort Wayne, IN 46845
Who else practices at this address →
Allen County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 178
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IN license 02005703A · MI license 5101010182
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Indiana University Health Ball Memorial Hospital Muncie, IN
- Insight Hospital and Medical Center Coldwater Coldwater, MI
- Indiana University Health Jay, Inc. Portland, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
- Indiana University Health Ball Memorial Physicians Inc (232 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 178
- Services billed
- 796
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 510 | 176 |
| Established patient office or other outpatient visit, 20-29 minutes | 33 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 29 | 11 |
| Established patient office or other outpatient visit, 40-54 minutes | 27 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Fort Wayne, IN | 148 |
| Acyclovir Other prescribers in Fort Wayne, IN | 119 |
| Xarelto (rivaroxaban) Other prescribers in Fort Wayne, IN | 98 |
| Lenalidomide | 51 |
| Allopurinol Other prescribers in Fort Wayne, IN | 40 |
| Calquence (acalabrutinib maleate) | 38 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Fort Wayne, IN | 38 |
| Potassium Chloride Other prescribers in Fort Wayne, IN | 35 |
| Revlimid (lenalidomide) | 33 |
| Hydroxyurea Other prescribers in Fort Wayne, IN | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 14 payments worth $4,333 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $4,078 |
|---|---|
| Secura Bio, Inc. | $99.31 |
| Novartis Pharmaceuticals Corporation | $83.86 |
| AbbVie Inc. | $45.48 |
| Tempus Ai, Inc | $26.80 |
| Consulting Fee | $2,875 |
|---|---|
| Travel and Lodging | $804 |
| Food and Beverage | $655 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Sep 27, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,875 |
| Syndax Pharmaceuticals, Inc. Sep 27, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL · in-kind | $337 |
| Syndax Pharmaceuticals, Inc. Sep 27, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL · in-kind | $193 |
| Syndax Pharmaceuticals, Inc. Sep 27, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL · in-kind | $142 |
| Syndax Pharmaceuticals, Inc. Sep 27, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ROSEMONT, IL | $132 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $65,675 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
AstraZeneca UK Limited - A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
Novartis Pharmaceuticals Corporation - A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First …
Novartis Pharmaceuticals Corporation - A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Novartis Pharmaceuticals Corporation - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05451810 - A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat MK-3543 versus Hydroxyurea in Cytoreductive Therapy Na ve Essential Thrombocythemia P…
Merck Sharp & Dohme LLC - M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc. - A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.